Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria.

Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them.

Through pioneering science and an unwavering commitment to patients, Alnylam has led the translation of the breakthrough discovery of RNA interference (RNAi) into an entirely new class of medicines that is disrupting disease.

At Alnylam we're 'change the world' kind of people. Explore career opportunities with a team that has pioneered RNAi therapeutics.

Find information about Alnylam's pharmaceutical products: ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and AMVUTTRA® (vutrisiran).

2024年10月9日 · Welcome to Capella, Alnylam’s destination for updates on our work translating the breakthrough discovery of RNA interference (RNAi) into an innovative new class of medicines.

2025年2月25日 · Alnylam is executing on its “ Alnylam P5x25 ” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in …

2024年4月7日 · Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in …

Since our founding in 2002, Alnylam has pioneered RNAi-based medicines through sustained research and development (R&D) efforts that have yielded the critical breakthroughs and innovations that make RNAi therapeutics possible.

2025年1月30日 · Read our most recent press releases and access our press release archive.